Abstract. Quercetin is a flavonoid that is widely present in plant-derived food. Quercetin-3-O-β-D-glucoside (Q3GA) is a predominant metabolite of quercetin in animal and human plasma. The inhibitory effects of the UDP-glucuronosyl transferases (UGTs) caused by herbal components may be a key factor for the clinical assessment of herb-drug interactions (HDIs). The present study aimed to investigate the inhibitory profile of quercetin and Q3GA on recombinant UGT1A isoforms in vitro. The metabolism of the nonspecific substrate 4-methylumbelliferone (4-MU) by the UGT1A isoforms was assessed by liquid chromatography-tandem mass spectrometry. Preliminary screening experiments indicated that quercetin exhibited stronger inhibitory effects on UGT1A1, UGT1A3, UGT1A6 and UGT1A9 enzymes than Q3GA. Kinetic experiments were performed to characterize the type of inhibition caused by quercetin and Q3GA towards these UGT isoforms. Quercetin exerted non-competitive inhibition on UGT1A1 and UGT1A6, with half maximal inhibitory concentration (IC\textsubscript{50}) values of 7.47 and 7.07 µM and inhibition kinetic parameter (K\textsubscript{i}) values of 2.18 and 28.87 µM, respectively. Quercetin also exhibited competitive inhibition on UGT1A3 and UGT1A9, with IC\textsubscript{50} values of 10.58 and 2.81 µM and K\textsubscript{i} values of 1.60 and 0.51 µM, respectively. However, Q3GA displayed weak inhibition on UGT1A1, UGT1A3 and UGT1A6 enzymes with IC\textsubscript{50} values of 45.21, 106.5 and 51.37 µM, respectively. In the present study, quercetin was a moderate inhibitor of UGT1A1 and UGT1A3, a weak inhibitor of UGT1A6, and a strong inhibitor on UGT1A9. The results of the present study suggested potential HDIs that may occur following quercetin co-administration with drugs that are mainly metabolized by UGT1A1, UGT1A3 and UGT1A9 enzymes.

Introduction

The flavonoid quercetin (3,3',4',5,7-pentahydroxyflavone; Fig. 1A) is one of the most abundant dietary polyphenols. It is mainly present in fruits and vegetables and ~3-40 mg quercetin is consumed in daily diets (1,2). Quercetin is widespread in the flowers, leaves and fruits of various plants and exhibits a multitude of pharmacological activities, including anti-neoplastic (3-5), anti-oxidative (6,7), anti-inflammatory (8,9), anti-thrombotic (10,11), antiviral (12,13), cardiovascular-protective (14,15) and immune-regulatory (16,17) effects. Isolated quercetin is a dietary supplement and its recommended maximum daily dosage is 1,000 mg (18). Following oral ingestion, quercetin is extensively conjugated with glucuronic acid and/or sulfate in the small intestine and liver. Quercetin-3-O-β-D-glucoside (Q3GA; Fig. 1B) is one of the primary metabolites found in the blood circulation (19). Q3GA exerts various pharmacological properties. Quercetin inhibits the viability of neural stem cells via the Akt signaling pathway. However, Q3GA provides a novel therapeutic potential in neurodegenerative diseases (20). In addition, the anti-inflammatory activity of Q3GA was evaluated by assessing the inhibition of LPS-induced NO release in vitro (21).
The biological activity of quercetin is notably affected by phase II, and not phase I, metabolism enzymes. As a plant-derived polyphenol, quercetin contains more than one free hydroxyl group, which makes it easy to be metabolized by different types of UGT enzyme isoforms, including UGT1A1s (22,23). UGTs are considered the indispensable enzymes of phase II metabolism and catalyze the conjugation of several endobiotics or xenobiotics with UDP-glucuronic acid in order to produce more hydrophilic metabolites that are easily excreted via the kidneys or the bile and the gut (24,25). CYP450-mediated herb-drug interactions (HDIs) have been previously investigated by in vitro assays using cocktails of probe substrates (26-29). Subsequent studies involving UGT enzymes have demonstrated that drug interactions based on the inhibition of UGTs may lead to clinically important side effects (30,31). Therefore, from a clinical point of view, the study of the inhibition of herbal compounds on UGT-mediated metabolism may aid the understanding of HDIs.

The in vitro UGT enzyme assay utilizes the nonspecific substrate 4-MU as a substrate and has various advantages over the use of human liver microsomes that include several specific probe-substrates (32). In the present study, the inhibition type and inhibitory effects of quercetin and its major metabolite Q3GA were assessed on various UGT isoforms (UGT1A1, UGT1A3, UGT1A6 and UGT1A9) by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This method was used to detect the changes in the concentration levels of 4-methylumbelliferyl-β-D-glucuronides (4-MU-G). This may provide insight into the potential HDIs regarding quercetin and Q3GA, providing the basis for further drug research and safe drug use.

Materials and methods

Chemicals and reagents. 4-MU and 4-MU-G were purchased from Shanghai Yuanye Bio-Technology Co., Ltd. Q3GA was purchased from Chengdu Sino Standards Bio-Tech Co., Ltd. 7-Hydroxycoumarin was obtained from Dalian Meilun Biotechnology Co., Ltd. Quercetin and uridine-5'-diphosphoglucuronic acid (UDPGA; trisodium salt) were purchased from Sigma-Aldrich (Merck KGaA). Recombinant human UGT isoforms (UGT1A1, UGT1A3, UGT1A6 and UGT1A9) were expressed in baculovirus-infected insect cells that, where applicable, were obtained from Corning, Inc. All other reagents were of the highest analytical grade commercially available. The specific reagents were sourced from companies mentioned previously (33).

Inhibition of recombinant UGTs-catalyzed 4-MU glucuronidation by quercetin and Q3GA. The experimental protocol and incubation has been accurately presented in previous studies (34-36). Typical incubations were performed in 200 µl reaction mixture containing 5 mM UDPGA, 5 mM MgCl₂, 50 mM Tris-HCl buffer (pH 7.4), 4-MU and recombinant UGTs. In addition, a series of quercetin concentrations and Q3GA were expressed in baculovirus-infected insect cells that, where applicable, were obtained from Corning, Inc. All other reagents were of the highest analytical grade commercially available. The specific reagents were sourced from companies mentioned previously (33).

The glucuronidation velocity of quercetin and Q3GA was determined at various 4-MU, quercetin or Q3GA concentrations. A preliminary screening experiment was performed to assess the inhibitory effects of quercetin and Q3GA. A total of 50 µM was selected for quercetin and Q3GA as the experimental group concentration. The remaining activity of UGTs=average concentration of 4-MU/UGT1A enzyme-quinertin/average concentration of 4-MU/UGT1A enzyme-blank x100%. The remaining activity of the blank group without quercetin and Q3GA was 100%.

Determination of inhibition kinetic parameters of quercetin and Q3GA on recombinant UGTs. The glucuronidation velocity was determined at various 4-MU, quercetin or Q3GA concentrations. A preliminary screening experiment was performed to assess the inhibitory effects of quercetin and Q3GA. A total of 50 µM was selected for quercetin and Q3GA as the experimental group concentration. The remaining activity of UGTs=average concentration of 4-MU/UGT1A enzyme-quinertin/average concentration of 4-MU/UGT1A enzyme-blank x100%. The remaining activity of the blank group without quercetin and Q3GA was 100%.

Detection of 4-MU-G by LC-MS/MS. 4-MU-G and 7-hydroxycoumarin (internal standard) were analyzed on an API-4000 triple quadruple mass spectrometer (Applied Biosystems; Thermo Fisher Scientific, Inc.) coupled with a Waters ACQUITY Ultra Performance Liquid Chromatograph (Waters Corporation). The separation was performed on an Inertil ODS-SP column (100x2.1 mm; 3 µm; GL Sciences) with a column temperature of 40°C. The mobile phase consisted of ultrapure water, containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). The following gradient conditions were used: 0-4.00 min, 5-80% B; 4.00-4.10 min, 80-5% B; 4.10-7.00 min, 5% B. The flow rate used was 0.2 ml/min, and the LC retention times of 4-MU-G and 7-hydroxycoumarin were 3.7 and 3.53 min, respectively. The turbo ion spray interface was operated at -4500 V and the ion source temperature was set at 500°C in the negative electrospray ionization mode. The multiple reaction monitoring (MRM) mode was employed for quantification using specific precursor/product ion transition. The precursor/product ion transitions were monitored at m/z 351.1→175.1 and 161.0→89.0 for 4-MU-G and 7-hydroxycoumarin, respectively. The optimized working parameters for mass detection of 4-MU-G and 7-hydroxycoumarin were as follows: i) Declustering potential, -50 and -80 V; ii) collision energy, -19 and -40 V; iii) curtain gas, 30 psi; iv) collision activated dissociation gas, 8 psi; v) Gas1, 55 psi and Gas2, 55 psi. The peak areas for all analytes were automatically integrated using the Analyst software (version 1.5.1; Applied Biosystems).

The specificity of this method was optimal. The linear range was estimated to be 50-5,000 ng/ml with the lower limit of quantification at 50 ng/ml. The RSD% of the intra-assay and inter-assay precisions were both <10%. The extraction recovery ranged between 100.99 and 106.34%. The internal standard normalized matrix factors for the low-, moderate- and high-quality control samples were 1.02, 1.07 and 0.99, respectively. The residues were negligible, and the samples were placed in a sampler at 4°C for 9 h and left at room temperature for 2 h.
in the incubation system. Five or six concentration ranges of quercetin and Q3GA were selected to assess the IC\textsubscript{50} values for the UGT1A enzymes. The concentration ranges of quercetin used were as follows: 0-10 µM for UGT1A1, 0-20 µM for UGT1A3 and 0-50 µM for UGT1A6 and UGT1A9. In addition, 0-50 µM Q3GA was selected for UGT1A1, UGT1A3 and UGT1A6. The IC\textsubscript{50} values of quercetin and Q3GA towards UGT1A enzyme activities were calculated by nonlinear regression analysis using the GraphPad Prism 5 (GraphPad Software, Inc.). When the remaining activities of these enzymes in the experimental groups were <50% of the control group, the K\textsubscript{i} was calculated. The K\textsubscript{i} resulted from fitting data into competitive inhibition, non-competitive inhibition, or mixed inhibition models. The type of inhibition was assessed graphically from the Lineweaver-Burk and Dixon plots (37).

**Results**

Inhibitory activities of quercetin and Q3GA on recombinant UGT1A isoforms. As shown in Table II, in the presence of 50 µM quercetin, the remaining activity of UGT1A1, UGT1A3, UGT1A6 and UGT1A9 enzymes were <8.4, <30.8, 23.1 and 11.7%, respectively, while the remaining activity of Q3GA on UGT1A1, UGT1A3, UGT1A6 and UGT1A9 was 36.1, 33.9, 28.4 and 74.2%, respectively. As the remaining activity of UGT1A isoforms was <50%, except for UGT1A9, quercetin and Q3GA exhibited inhibitory effects on UGT1A1, UGT1A3, UGT1A6 and UGT1A9 enzymes.

In the presence of 50 µM quercetin, the final concentrations of the metabolite 4-MUG were too low to detect in UGT1A1 and UGT1A3 incubation systems. However, the lowest limit of quantitation for 4-MUG was 50 ng/ml in the present study. The remaining activity of UGT1A1 enzymes <50 ng/ml/593 ng/ml\times100%=8.4%, and the remaining activity of UGT1A1 enzymes <50 ng/ml/162.3 ng/ml\times100%=30.8%. Therefore, the remaining activities of UGT1A1 and UGT1A3 were less than 8.4 and 30.8%, respectively.

Inhibition type and kinetics of quercetin towards UGT1A1, UGT1A3, UGT1A6 and UGT1A9. The inhibitory parameters of quercetin on these UGT isoforms were characterized/calculated by further kinetic experiments. Quercetin inhibited UGT1A1, UGT1A3, UGT1A6 and UGT1A9 activity in a dose-dependent manner and the IC\textsubscript{50} values were 7.47, 10.58, 7.07 and 2.81 µM, respectively (Figs. 2A, 3A, 4A and 5A). Furthermore, the inhibition types were determined from Dixon and Lineweaver-Burk plots. As shown in Fig. 2B and D and in Fig. 4B and D, the inhibitory effect of quercetin on UGT1A1 and UGT1A6-catalyzed 4-MU glucuronidation was characterized as non-competitive inhibition, while the inhibitory activity of quercetin on UGT1A3 and UGT1A6 was characterized as competitive inhibition (Figs. 3B and D; 5B and D). The calculated K\textsubscript{i} were 2.18, 1.60, 28.87 and 0.51 µM for the inhibitory effect of quercetin on UGT1A1, UGT1A3, UGT1A6 and UGT1A9, respectively (Figs. 2C, 3C, 4C and 5C).

Inhibition type and kinetics of Q3GA towards UGT1A1, UGT1A3 and UGT1A6. Preliminary screening experiments indicated that Q3GA exhibited inhibitory effects on UGT1A1, UGT1A3 and UGT1A6. The parameters of the kinetic experiments are presented in Fig. 6. The inhibitory activity of Q3GA on UGT1A1, UGT1A3 and UGT1A6 enzymes was dose-dependent, with IC\textsubscript{50} values of 45.21, 106.5 and 51.37 µM, respectively. Therefore, Q3GA may display weakly inhibit UGT1A1, UGT1A3 and UGT1A6.

**Discussion**

In recent years, dietary supplements and alternative medicine therapies have become increasingly accepted. A previous study (38) has demonstrated that the absorption and disposition of the active ingredients of dietary supplements are significant in determining their biological activity. In addition, accumulated evidence with regard to HDIs between drug-metabolizing enzymes and drug transporters may be used to predict the pharmacokinetic profile of drugs and the underlying HDIs (39,40). These potential interactions may cause significant risks to the patients, particularly for drugs with narrow therapeutic indices.

It has been demonstrated that quercetin may prevent cyclosporine A-induced nephrotoxicity and hepatotoxicity (41,42) as it exerts various effects on the pharmacokinetics of cyclosporine A. However, the underlying mechanisms for these interactions remain unclear. Our previous studies have demonstrated that Q3GA increases the C\textsubscript{max}, AUC\textsubscript{0-16} and AUC\textsubscript{0-∞} of cyclosporine A (19,43). In order to further elucidate the underlying mechanisms of quercetin and Q3GA on the pharmacokinetics of cyclosporine A, the inhibitory effects of quercetin and Q3GA on the enzyme activity of recombinant UGT1A isoforms were investigated \textit{in vitro}.

Figure 1. Chemical structures of (A) Quercetin and (B) Q3GA. Q3GA, quercetin-3-O-β-D-glucoside.
The inhibitory potential of the compounds was determined based on their Ki values and they were classified as potent inhibitors (Ki<1 µM), moderate inhibitors (1 µM < Ki<10 µM) and weak inhibitors (Ki>10 µM). Based on the IC₅₀ values of Q3GA on UGT1A1, UGT1A3 and UGT1A6 enzymes that were much higher than 10 µM, and the fact that the remaining activity of UGT1A9 was >50% following Q3GA incubation, these data suggested that Q3GA displayed limited inhibitory effects on these UGT isoforms. Therefore, the subsequent enzymatic kinetics experiments were not performed, so the inhibition constant Ki of Q3GA on UGT1A enzymes could not be calculated. However, quercetin was more active in suppressing the activity of UGT isoforms compared with Q3GA. Its inhibitory effect on UGT1A1 and UGT1A6 was noncompetitive, with IC₅₀ values of 7.47 and 7.07 µM, respectively, and Ki values of 2.18 and 2.87 µM, respectively. By contrast to these two isoforms, quercetin inhibited UGT1A3 and UGT1A9 competitively with IC₅₀ values of 10.58 and 2.81 µM, respectively, and Ki values of 1.60 and 0.51 µM, respectively. These results indicated that quercetin was a moderate inhibitor of UGT1A1 and UGT1A3, and a strong inhibitor of UGT1A9, while Q3GA exhibited weak inhibitory effects on the activity of UGT1A1, UGT1A3, UGT1A6 and UGT1A9 isoforms. There was a small slope in Fig. 4C, which may be due to the fact that quercetin only exerted a weak inhibitory effect on UGT1A6. Furthermore, in the UGT1A3 incubation system, the inhibitory effect of 5 µM quercetin did not have a linear relationship with the inhibitory effect of other concentrations of quercetin, which may be the reason for the small slope in Fig. 3C.

Quercetin and Q3GA exhibited similar inhibitory effects on the protein and mRNA expression levels of UGT1A1 in the small intestine and the liver. This is consistent with our preliminary data and previously published studies (19,43). It has also been reported that quercetin inhibits glucuronidation of ethanol in human liver microsomes and in recombinant UGT1A1, UGT1A3, UGT1A4, UGT1A6 and UGT1A9 enzymes (44). However, quercetin has been reported to induce UGT1A6 mRNA expression in human intestinal tissues in vitro (45). Notably, quercetin induces UGT1A expression in Caco-2 cells (46). It has also been reported that this flavonoid increases UGT enzyme activities in hepatic, and small and large intestinal tissues of male Wistar rats (47). A previous study has reported that the age-associated differences in the UGT-catalyzed glucuronidation of quercetin depend on the intestinal segment, particularly the proximal and distal segments (48). In brief, humans and animals express different protein and activity levels of UGT1A isoforms.

There are limitations to the present study, including the fact that quercetin or Q3GA were added separately to the UGT1A incubation systems evaluate their inhibitory effects. However, to the best of our knowledge, there are no effective methods to distinguish the role of the quercetin/Q3GA vs. quercetin plus Q3GA, as quercetin may be metabolized to Q3GA by UGT1A in the incubation (49‑51), and Q3GA may be hydrolyzed to quercetin in the incubation in activated mouse macrophages (49). The results of the present study demonstrated that the inhibitory effects of quercetin and Q3GA on UGT1A enzymes were significantly different. Additionally, compared with quercetin, the inhibitory effect of Q3GA on UGT1A enzymes was very weak. Therefore, we hypothesized that Q3GA had a separate inhibitory effect on the UGT1A enzymes, rather than inhibiting the UGT1A enzymes through hydrolysis to quercetin.

A previous study (52) has reported that 3-hydroxyflavone has a higher catalytic rate than 7-hydroxyflavone, due to differences in the hydroxyl positions. Therefore, following conjugation of the C-3 hydroxyl group with the glucuronic acid to yield Q3GA, a decrease in the catalytic rate of Q3GA may be noted. In addition, Boersma et al (53) reported that quercetin inhibited UGT1A6 less efficiently than luteolin, which was possibly due to the lack of the C-3 hydroxyl group. This result suggested that flavonoids without the C-3 hydroxyl group exhibit a significant inhibitory effect on the UGT1A6-catalyzed reaction. This blocking effect is more pronounced for UGT1A6 when a larger group is conjugated with the C-3 hydroxyl group. In general, when Q3GA and quercetin

| Table I. Substrate concentration, enzyme concentration and incubation time of each UGT enzyme. |
|---------------------------------------------------------------|
| UGT enzyme | Enzyme concentration, mg/ml | Incubation time, min | Substrate concentration, µM |
| UGT1A1 | 0.125 | 120 | 30 |
| UGT1A3 | 0.05 | 120 | 1,200 |
| UGT1A6 | 0.025 | 30 | 110 |
| UGT1A9 | 0.05 | 30 | 30 |

UGT, UDP-glucuronosyltransferase.

| Table II. Preliminary inhibition screening of quercetin and Q3GA toward activities of recombinant UGT1A isoforms. |
|---------------------------------------------------------------|
| UGT1A enzyme | Remaining enzyme activity | Quercetin, (%) | Q3GA, (%) |
| UGT1A1 | <8.4 | 36.1 |
| UGT1A3 | <30.8 | 33.9 |
| UGT1A6 | 23.1 | 28.4 |
| UGT1A9 | 11.7 | 74.2 |

Q3GA, quercetin-3-O-β-D-glucoside; UGT, UDP-glucuronosyltransferase.
are combined with UGT1As, the steric hindrance effect of Q3GA greatly decreases the rate and extent of this catalytic reaction.

In conclusion, the results of the present study indicated that the inhibitory effect of quercetin on UGT1A1, UGT1A3, UGT1A6 and UGT1A9 was more potent than that of Q3GA. Furthermore, the results demonstrated that quercetin was a moderate inhibitor of UGT1A1 and UGT1A3, and a strong inhibitor of UGT1A9, and therefore HDIs may occur when
Figure 4. Determination of the inhibitory effect of quercetin on UGT1A6, and the kinetic parameters. (A) Dose-dependent inhibitory effect of quercetin on recombinant UGT1A6-catalyzed 4-MU glucuronidation. (B) Dixon plot of the inhibitory effect of quercetin on recombinant UGT1A6-catalyzed 4-MU glucuronidation. (C) Second plot comparing the slopes from the Lineweaver-Burk plot with the concentrations of quercetin. (D) Lineweaver-Burk plot of the inhibitory effect of quercetin on recombinant UGT1A6-catalyzed 4-MU glucuronidation. UGT, UDP-glucuronosyltransferase; 4-MU, 4-methylumbelliferone; Que, quercetin.

Figure 5. Determination of the inhibitory effect of quercetin on UGT1A9, and the kinetic parameters. (A) Dose-dependent inhibitory effects of quercetin on recombinant UGT1A9-catalyzed 4-MU glucuronidation. (B) Dixon plot of the inhibitory effect of quercetin on recombinant UGT1A9-catalyzed 4-MU glucuronidation. (C) Second plot comparing the slopes from the Lineweaver-Burk plot with the concentrations of quercetin. (D) Lineweaver-Burk plot of the inhibitory effect of quercetin on recombinant UGT1A9-catalyzed 4-MU glucuronidation. UGT, UDP-glucuronosyltransferase; 4-MU, 4-methylumbelliferone; Que, quercetin.

Figure 6. Determination of IC_{50} values of (A) UGT1A1, (B) UGT1A3 and (C) UGT1A6 enzymatic activity.
quercetin is co-administered with drugs that are mainly metabolized by UGT1A1, UGT1A3 and UGT1A9.

Acknowledgements
Not applicable.

Funding
The present study was supported by the National Natural Science Foundation of China (grant nos. 81874326 and 81503161); The Chinese Medicine Research Project of Health Commission of Hubei Province (grant no. ZY2019Z004); and the National Key R&D Program of China (grant no. 2017YFC0909900).

Availability of data and materials
All data generated and/or analyzed during this study are included in this published article.

Authors’ contributions
RZ, YL and SS designed all the experiments. YW and TY performed the incubation experiments. Statistical analysis was performed by XH, JZ, JNZ and CY. YL and SS confirm the authenticity of all the raw data. YW, RZ, YL and SS wrote the manuscript. All authors read and approved the final manuscript. RZ, YL and SS wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Babaei F, Mirzababaei M and Nassiri-Asl M: Quercetin in food: Possible mechanisms of its effect on memory. J Food Sci 83: 2280-2287, 2018.
2. Costa LG, Garrick JM, Roque PJ and Pellacani C: Mechanisms of neuroprotection by quercetin: Counteracting oxidative stress and more. Oxid Med Cell Longev 2016: 2986796, 2016.
3. Jana N, Brestislaw G, Pavel S and Pavla U: Potential of the flavonoid quercetin to prevent and treat cancer-current status of research. Klin Onkol 31: 184-190, 2018.
4. Primikyri A, Sayyad N, Quilici G, Vrettos EI, Lim K, Chi SW, Musco G, Gerothanassis IP and Tzakos AG: Probing the interaction of a quercetin bisconjugate with Bcl-2 in living human cancer cells with in-cell NMR spectroscopy. FEBS Lett 592: 3367-3379, 2018.
5. Sharmila G, Athirai T, Kiruthiga B, Senthilkumar K, Elumalai P, Arunkumar R and Arunakaran J: Chemopreventive effect of quercetin in MNU and testosterone induced prostate cancer of sprague-dawley rats. Nutr Cancer 66: 38-46, 2014.
6. Tang SH, Li R, Tan J, Wang Y and Jiang ZT: One pot synthesis of water-soluble quercetin derived multifunctional nanoparticles with photothermal and antioxidant capabilities. Colloids Surf B Biointerfaces 183: 110429, 2019.
7. Zheng YZ, Deng G, Liang Q, Chen DF, Guo R and Lai RC: Antioxidant activity of quercetin and its di-glucosides from propolis: A theoretical study. Sci Rep 7: 7543, 2017.
8. Newton K and Dixit VM: Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol 4: a006049, 2012.
9. Byun EB, Yang MS, Choi HG, Sung NY, Song DS, Sin SJ and Byun EH: Quercetin negatively regulates IL-6 expression induced by lipopolysaccharide through tollip expression. Biochem Biophys Res Commun 431: 698-705, 2013.
10. Lee SM, Moon J, Chung JH, Cha YJ and Shin MJ: Effect of quercetin-rich onion peel extracts on arterial thrombosis in rats. Food Chem Toxicol 57: 99-105, 2013.
11. Pan W, Chang MJ, Booyse FM, Grenett HE, Bradford KM, Wolkowicz PE, Shang Q and Tabengwa EM: Quercetin induced tissue-type plasminogen activator expression is mediated through Splt and p38 mitogen-activated protein kinase in human endothelial cells. J Thromb Haemost 6: 976-985, 2008.
12. Qin X, Kroezer A, He S, Kozak R, Audeit J, Mbikay M and Chrétien M: Prophylactic efficacy of quercetin 3-β-D-glucoside against ebola virus infection. Antimicrob Agents Chemother 60: 5182-5188, 2016.
13. Gonzalez O, Fontanes V, Raychadhuri S, Loo R, Loo J, Aramugaswami V, Sun R, Dasgupta A and French SW: The heat shock protein inhibitor quercetin attenuates hepatitis C virus production. Hepatology 50: 1756-1764, 2009.
14. Liu H, Guo X, Chu Y and Lu S: Heart protective effects and mechanism of quercetin preconditioning on anti-myocardial ischemia reperfusion (IR) injuries in rats. Gene 545: 149-155, 2014.
15. Lin R, Liu J, Gan W and Ding C: Protective effect of quercetin on the homocysteine-injured human umbilical vein vascular endothelial cell line (ECV304). Basic Clin Pharmacol Toxicol 101: 197-202, 2007.
16. Kobori M, Takahashi Y, Sakurai M, Akimoto Y, Tushida T, Oike H and Ippoushi K: Quercetin suppresses immune cell accumulation and improves mitochondrial gene expression in adipose tissue of diet-induced obese mice. Mol Nutr Food Res 60: 302-310, 2016.
17. Singh D, Tanwar H, Jayashankar B, Sharma J, Murthy S, Chanda S, Singh SB and Ganju L: Quercetin exhibits adjudvant activity by enhancing Th2 immune response in ovalbumin immunized mice. Biomed Pharmacother 90: 354-360, 2017.
18. Andres S, Pevny S, Ziegenhagen R, Bakhinya N, Schäfer B, Hirsch-Ernest KI and Lampen A: Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res 62, 2018.
19. Wang T, Liu Y, Huang X, Zhang R, Yang C, Zhou J, Zhang Y, Wang J and Shi S: Quercetin-3-O-β-D-glucoside decreases bioavailability of cyclosporin A through regulation of drug metabolizing enzymes, transporters and nuclear receptors in rats. Mol Med Rep 18: 2599-2612, 2018.
20. Baral S, Pariyar R, Kim J, Lee HS and Seo J: Quercetin-3-O-glucuronide promotes the proliferation and migration of neural stem cells. Neurobiol Aging 52: 39-52, 2017.
21. Li F, Sun XY, Li XW, Yang T and Qi LW: Enrichment and separation of quercetin-3-O-β-glucuronide from lotus leaves (nelumbo nucifera gaertn.) and evaluation of its anti-inflammatory effect. J Chromatogr B Analyt Technol Biomed Life Sci 1040: 186-191, 2017.
22. Oliveira EJ and Watson DG: In vitro glucuronidation of kaempferol and quercetin by human UGT-1A9 microsomes. FEBS Lett 471: 1-6, 2000.
23. Zhou H, Shi R, Ma B, Ma Y, Wang C, Wu D, Wang X and Cheng N: CYP450 1A2 and multiple UGT1A1 isoforms are responsible for jitterrhonise metabolism in human liver microsomes. Biopharm Drug Dispos 34: 176-185, 2013.
24. Stengl JC, Bartels H, Viviani R, Lehmann ML and Brockmöller J: Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther 141: 92-116, 2014.
25. Miners JO, Mackenzie PI and Knights KM: The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vivo-in vitro extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42: 196-208, 2010.
26. Jeong HU, Lee JY, Kwon SS, Kim JH, Kim YM, Hong SW, Yeon SH, Lee SM, Cho YY and Lee HS: Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes. Arch Pharm Res 38: 171-177, 2015.

27. Tan ML and Lim LE: The effects of Andrographis paniculata (Burm.f.) Nees extract and diterpenoids on the CYP450 isozymes' activities, a review of possible herb-drug interaction risks. Drug Chem Toxicol 38: 241-253, 2015.

28. Li G, Huang K, Nikolic D and van Bremen RB: High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions. Drug Metab Dispos 43: 1670-1678, 2015.

29. Weissenstein U, Kunz M, Oufir M, Wang JT, Hamburger M, Urech K, Regueiro U and Baumgartner S: Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med 19: 23, 2019.

30. Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, Weisbaum G, Trakis AG and Schiff ER: Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 28: 1188-1193, 2008.

31. Magee CN, Medani SA, Leavey SF, Conlon PJ and Clarkson MR: Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. Am J Kidney Dis 56: e11-e15, 2010.

32. Huang T, Fang ZZ and Yang L: Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug-drug interaction. Pharmazie 65: 919-921, 2010.

33. Lu H, Fang ZZ, Cao YF, Hu CM, Hong M, Sun XY, Li H, Liu Y, Fu X and Sun H: Isoflavonoidifen showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase (UGT) isoform-catalyzed 4-methylumbelliferone (4-MU) glucuronidation. Fitoterapia 84: 208-212, 2013.

34. Liu C, Cao YF, Fang ZZ, Zhang YY, Hu CM, Sun XY, Huang T, Zeng J, Fan XR and Mo H: Strong inhibition of deoxyschizandrin and schisandrin A toward UDP-glucuronosyltransferase (UGT) 1A3 indicating UGT inhibition-based drug-drug interaction. Fitoterapia 83: 1415-1419, 2012.

35. Jiang HM, Fang ZZ, Cao YF, Hu CM, Sun XY, Hong M, Yang L, Ge GB, Liu Y, Zhang YY, et al: New insights for the risk of bisphenol A: Inhibition of UDP-glucuronosyltransferases (UGTs). Chemosphere 93: 1189-1193, 2013.

36. Sun D, Zhang CZ, Ran RX, Cao YF, Du Z, Fu ZW, Huang CT, Zhao ZY, Zhang WH and Fang ZZ: In vitro comparative study of the inhibitory effects of mangiferin and its aglycone nor-mangiferin towards UDP-glucuronosyltransferase (UGT) isoenzymes. Molecules 22: 1008, 2017.

37. Zhu L, Ge G, Liu Y, He G, Liang S, Fang Z, Dong P, Cao Y and Yang L: Potent and selective inhibition of mangiferin on catalytic activities of UGT1A7 and 1A9. Xenobiotica 42: 1001-1008, 2012.

38. Miclaus MO, Filip X, Filip C, Martin FA and Grou G: Highly sensitive solid forms discrimination on the whole tablet of the active ingredients in quercetin dietary supplements by NMR crystallography approaches. J Pharm Biomed Anal 124: 274-280, 2016.

39. Shi S and Li Y: Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition. Curr Drug Metab 15: 915-941, 2014.

40. Wu B: Pharmacokinetic interplay of phase II metabolism and transport: A theoretical study. J Pharm Sci 101: 381-393, 2012.

41. Zaf F, Mostafavi-Pour Z and Vessal M: Comparison of the effects of vitamin E and/or quercetin in attenuating chronic cyclosporine A-induced nephrotoxicity in male rats. Clin Exp Pharmacol Physiol 34: 720-724, 2007.

42. Mostafavi-Pour Z, Zaf F, Monabati A and Vessal M: Protective effects of a combination of quercetin and vitamin E against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Hepatol Res 38: 385-392, 2008.

43. Liu Y, Luo X, Yang C, Yang T, Zhou J and Shi S: Impact of quercetin-induced changes in drug-metabolizing enzyme and transporter expression on the pharmacokinetics of cyclosporine in rats. Mol Med Rep 14: 3073-3085, 2016.

44. Stachel N and Skopp G: Formation and inhibition of ethyl glucuronide and ethyl sulfate. Forensic Sci Int 265: 61-64, 2016.

45. van de Kerkhof EG, de Graaf IA, Ungell AL and Groothuis GM: Induction of metabolism and transport in human intestine: Validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro. Drug Metab Dispos 36: 604-613, 2008.

46. Galijatovic A, Walle UK and Walle T: Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res 17: 21-26, 2000.

47. van der Logt EM, Roelofs HM, Nengast FM and Peters WH: Induction of rat hepatic and intestinal UDP-glucuronosyltransferases by naturally occurring dietary anticarcinogens. Carcinogenesis 24: 1651-1656, 2003.

48. Bolling BW, Court MH, Blumberg JB and Chen CY: Microsomal quercetin glucuronidation in rat small intestine depends on age and segment. Drug Metab Dispos 39: 1406-1414, 2011.

49. Kawai Y, Nishikawa T, Shibya S, Saito S, Murota K, Shibata N, Kobayashi M, Kanayama M, Uchida K and Terao J: Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: Implication in the anti-atherosclerotic mechanism of dietary flavonoids. J Biol Chem 283: 9424-9434, 2008.

50. Ishizawa K, Yoshizumi M, Kawai Y, Terao J, Kihira Y, Ikeda Y, Tomita S, Minakuchi K, Tsujiya K and Tamaki T: Pharmacology in health food: Metabolism of quercetin in vivo and its protective effect against arteriosclerosis. J Pharmacol Sci 115: 466-470, 2011.

51. Chao CL, Hou YC, Chao PD, Weng CS and Ho FM: The antioxidant effects of quercetin metabolites on the prevention of high glucose-induced apoptosis of human umbilical vein endothelial cells. Brit J Nutr 110: 1165-1170, 2009.

52. Senafi SB, Clarke DJ and Burchell B: Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 397: 233-240, 1994.

53. Boersma MG, van der Woude H, Bogaards J, Boeren S, Vervoort J, Cnubben NH, van Iersel ML, van Bladeren PJ and Boersma MG: Highly sensitive solid forms discrimination on the whole tablet of the active ingredients in quercetin dietary supplements by NMR crystallography approaches. J Pharm Biomed Anal 124: 274-280, 2016.

54. Shi S and Li Y: Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition. Curr Drug Metab 15: 915-941, 2014.